Details of the Drug Reposition

General Information of This Drug (ID: DMJV2IF)

Drug Name
JCAR017   DMJV2IF
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
leukaemia DISS7D1V 2A60-2B33 Phase 1/2 [1]
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1/2 [2]
------------------------------------------------------------------------------------
4 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Follicular lymphoma DISVEUR6 2A80 Phase 1 [3]
Primary mediastinal B-cell lymphoma DIS7PRLV 2A81 Phase 1 [3]
Mantle cell lymphoma DISFREOV 2A85.5 Phase 1 [2]
B-cell non-hodgkin lymphoma DISUB5FB 2B33.5 Phase 1 [4]
------------------------------------------------------------------------------------
1 Clinical trial Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Clinical trial [2]
------------------------------------------------------------------------------------

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041076)
2 ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
3 ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)